S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
S&P 500   4,228.48 (-1.29%)
DOW   33,706.74 (-0.86%)
QQQ   322.86 (-1.95%)
AAPL   171.52 (-1.51%)
MSFT   286.15 (-1.39%)
META   167.96 (-3.84%)
GOOGL   117.21 (-2.46%)
AMZN   138.23 (-2.86%)
TSLA   890.00 (-2.05%)
NVDA   178.49 (-4.92%)
NIO   19.05 (-4.32%)
BABA   89.63 (-1.22%)
AMD   95.95 (-4.47%)
T   18.43 (+0.00%)
MU   60.51 (-3.92%)
CGC   3.82 (+0.26%)
F   15.88 (-1.67%)
GE   77.72 (-1.88%)
DIS   120.14 (-2.06%)
AMC   18.02 (-6.58%)
PYPL   96.56 (-3.30%)
PFE   49.15 (+1.17%)
NFLX   241.16 (-1.64%)
NASDAQ:AMGN

Amgen - AMGN Stock Forecast, Price & News

$250.86
+1.16 (+0.46%)
(As of 08/19/2022 12:00 AM ET)
Add
Compare
Today's Range
$247.63
$252.01
50-Day Range
$230.71
$253.15
52-Week Range
$198.64
$258.45
Volume
2.21 million shs
Average Volume
3.09 million shs
Market Capitalization
$134.19 billion
P/E Ratio
21.26
Dividend Yield
3.11%
Price Target
$245.14

Amgen MarketRank™ Forecast

Analyst Rating
Hold
2.13 Rating Score
Upside/​Downside
2.3% Downside
$245.14 Price Target
Short Interest
Healthy
3.24% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.42
Upright™ Environmental Score
News Sentiment
0.34mentions of Amgen in the last 14 days
Based on 22 Articles This Week
Insider Trading
Selling Shares
$150,000 Sold Last Quarter
Proj. Earnings Growth
9.93%
From $17.42 to $19.15 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.72 out of 5 stars

Medical Sector

91st out of 1,116 stocks

Biological Products, Except Diagnostic Industry

11th out of 178 stocks

AMGN stock logo

About Amgen (NASDAQ:AMGN) Stock

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Analyst Ratings Changes

A number of analysts have issued reports on AMGN shares. Oppenheimer reissued a "buy" rating and issued a $290.00 price objective on shares of Amgen in a report on Wednesday, August 10th. TheStreet raised shares of Amgen from a "c+" rating to a "b" rating in a report on Monday. Atlantic Securities cut their price target on shares of Amgen from $190.00 to $182.00 and set an "underweight" rating for the company in a report on Tuesday, August 9th. StockNews.com downgraded shares of Amgen from a "strong-buy" rating to a "buy" rating in a report on Monday, August 8th. Finally, Piper Sandler upped their price target on shares of Amgen from $260.00 to $265.00 and gave the stock an "overweight" rating in a report on Friday, August 5th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and five have given a buy rating to the company's stock. According to MarketBeat.com, Amgen presently has a consensus rating of "Hold" and an average target price of $245.14.

Amgen Price Performance

AMGN opened at $249.70 on Friday. The company has a market capitalization of $133.57 billion, a price-to-earnings ratio of 21.16, a PEG ratio of 2.05 and a beta of 0.56. The company has a quick ratio of 1.17, a current ratio of 1.53 and a debt-to-equity ratio of 14.76. The firm has a 50-day moving average price of $245.29 and a 200-day moving average price of $241.27. Amgen has a twelve month low of $198.64 and a twelve month high of $258.45.

Amgen (NASDAQ:AMGN - Get Rating) last posted its earnings results on Thursday, August 4th. The medical research company reported $4.65 earnings per share for the quarter, topping the consensus estimate of $4.40 by $0.25. The firm had revenue of $6.59 billion during the quarter, compared to the consensus estimate of $6.53 billion. Amgen had a net margin of 24.92% and a return on equity of 218.34%. The company's revenue was up 1.0% on a year-over-year basis. During the same quarter last year, the company earned $4.38 earnings per share. Equities analysts expect that Amgen will post 17.42 EPS for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 8th. Stockholders of record on Thursday, August 18th will be paid a $1.94 dividend. The ex-dividend date of this dividend is Wednesday, August 17th. This represents a $7.76 annualized dividend and a dividend yield of 3.11%. Amgen's payout ratio is 65.76%.

Insider Transactions at Amgen

In other news, Director R Sanders Williams sold 600 shares of the firm's stock in a transaction that occurred on Monday, May 23rd. The shares were sold at an average price of $250.00, for a total value of $150,000.00. Following the completion of the transaction, the director now directly owns 5,501 shares in the company, valued at $1,375,250. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.46% of the company's stock.

Receive AMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.

AMGN Stock News Headlines

Two Appealing Biotech Stocks for Two Distinct investors (AMGN)
Investing in biotech stocks carries both risk and reward. This article highlights two biotech companies that may appeal to specific investing styles
Should You Buy AbbVie Ahead Of Earnings? (AMGN)
AbbVie (NYSE: ABBV) is due to announce its earnings over the next couple of days. Some investors are considering buying it in advance, but it is worth the investment?
Amgen (NASDAQ:AMGN) Upgraded by TheStreet to "B"
5 Biotech Stocks in the Buy Zone This Week
Dogs of the Dow: 2 Stocks to Buy and 2 to Hold
Amgen (NASDAQ:AMGN) Stock Rating Reaffirmed by Oppenheimer
Amgen (NASDAQ:AMGN) Rating Lowered to Buy at StockNews.com
See More Headlines
Receive AMGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amgen and its competitors with MarketBeat's FREE daily newsletter.

AMGN Company Calendar

Ex-Dividend for 6/8 Dividend
5/16/2022
Dividend Payable
6/08/2022
Last Earnings
8/04/2022
Ex-Dividend for 9/8 Dividend
8/17/2022
Today
8/19/2022
Dividend Payable
9/08/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:AMGN
CUSIP
03116210
Employees
24,200
Year Founded
1980

Price Target and Rating

Average Stock Price Forecast
$245.14
High Stock Price Forecast
$290.00
Low Stock Price Forecast
$182.00
Forecasted Upside/Downside
-2.3%
Consensus Rating
Hold
Rating Score (0-4)
2.13
Research Coverage
16 Analysts

Profitability

Net Income
$5.89 billion
Pretax Margin
28.40%

Debt

Sales & Book Value

Annual Sales
$25.98 billion
Cash Flow
$23.67 per share
Book Value
$4.52 per share

Miscellaneous

Free Float
532,470,000
Market Cap
$134.19 billion
Optionable
Optionable
Beta
0.56

Social Links


Key Executives

  • Mr. Robert A. BradwayMr. Robert A. Bradway (Age 59)
    Chairman, CEO & Pres
    Comp: $5.81M
  • Mr. Peter H. GriffithMr. Peter H. Griffith (Age 63)
    Exec. VP & CFO
    Comp: $2.66M
  • Mr. Esteban Santos (Age 54)
    Exec. VP of Operations
    Comp: $2.61M
  • Dr. David M. Reese M.D. (Age 59)
    Exec. VP of R&D
    Comp: $2.79M
  • Mr. Murdo Gordon (Age 55)
    Exec. VP of Global Commercial Operations
    Comp: $2.82M
  • Ms. Linda H. Louie
    VP of Fin. & Chief Accounting Officer
  • Mr. Mike Zahigian
    Sr. VP & Chief Information Officer
  • Mr. Arvind Sood
    VP of Investor Relations
  • Mr. Jonathan P. GrahamMr. Jonathan P. Graham (Age 61)
    Exec. VP, Gen. Counsel & Sec.
  • Ms. Nancy A. GrygielMs. Nancy A. Grygiel (Age 54)
    Sr. VP of Worldwide Compliance & Bus. Ethics and Chief Compliance Officer













AMGN Stock - Frequently Asked Questions

Should I buy or sell Amgen stock right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 2 sell ratings, 10 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AMGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
View AMGN analyst ratings
or view top-rated stocks.

What is Amgen's stock price forecast for 2022?

16 Wall Street analysts have issued 12-month target prices for Amgen's shares. Their AMGN share price forecasts range from $182.00 to $290.00. On average, they predict the company's share price to reach $245.14 in the next year. This suggests that the stock has a possible downside of 2.3%.
View analysts price targets for AMGN
or view top-rated stocks among Wall Street analysts.

How have AMGN shares performed in 2022?

Amgen's stock was trading at $224.97 on January 1st, 2022. Since then, AMGN shares have increased by 11.5% and is now trading at $250.86.
View the best growth stocks for 2022 here
.

When is Amgen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our AMGN earnings forecast
.

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) released its earnings results on Thursday, August, 4th. The medical research company reported $4.65 earnings per share for the quarter, beating the consensus estimate of $4.40 by $0.25. The medical research company had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.53 billion. Amgen had a trailing twelve-month return on equity of 218.34% and a net margin of 24.92%. The company's revenue for the quarter was up 1.0% on a year-over-year basis. During the same period in the previous year, the firm posted $4.38 EPS.
Read the conference call transcript
.

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen declared a quarterly dividend on Wednesday, August 3rd. Investors of record on Thursday, August 18th will be given a dividend of $1.94 per share on Thursday, September 8th. This represents a $7.76 dividend on an annualized basis and a yield of 3.09%. The ex-dividend date of this dividend is Wednesday, August 17th.
Read our dividend analysis for AMGN
.

Is Amgen a good dividend stock?

Amgen (NASDAQ:AMGN) pays an annual dividend of $7.76 per share and currently has a dividend yield of 3.11%. The company has been increasing its dividend for 11 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 65.76%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, AMGN will have a dividend payout ratio of 40.52% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for AMGN.

What guidance has Amgen issued on next quarter's earnings?

Amgen issued an update on its FY 2022 earnings guidance on Thursday, August, 18th. The company provided EPS guidance of $17.00-$18.00 for the period, compared to the consensus EPS estimate of $17.40. The company issued revenue guidance of $25.50 billion-$26.40 billion, compared to the consensus revenue estimate of $26.23 billion.

What is Robert A. Bradway's approval rating as Amgen's CEO?

1,239 employees have rated Amgen Chief Executive Officer Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among the company's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 81.0% of employees surveyed would recommend working at Amgen to a friend.

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and Home Depot (HD).

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Who are Amgen's major shareholders?

Amgen's stock is owned by a variety of institutional and retail investors. Top institutional investors include State Street Corp (5.47%), Primecap Management Co. CA (2.92%), FMR LLC (1.67%), Northern Trust Corp (1.36%), Deutsche Bank AG (0.91%) and UBS Asset Management Americas Inc. (0.65%). Insiders that own company stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, Jonathan P Graham, Nancy A Grygiel, Nancy A Grygiel, R Sanders Williams, Ronald D Sugar and Ronald D Sugar.
View institutional ownership trends
.

How do I buy shares of Amgen?

Shares of AMGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $250.86.

How much money does Amgen make?

Amgen (NASDAQ:AMGN) has a market capitalization of $134.19 billion and generates $25.98 billion in revenue each year. The medical research company earns $5.89 billion in net income (profit) each year or $11.80 on an earnings per share basis.

How many employees does Amgen have?

The company employs 24,200 workers across the globe.

Does Amgen have any subsidiaries?
The following companies are subsidiares of Amgen: Abgenix, Alantos Pharmaceuticals, Amgen Canada Inc., Amgen Europe GmbH, Amgen Fremont Inc., Amgen Global Finance B.V., Amgen GmbH Germany, Amgen Ilaç Ticaret Limited Şirketi, Amgen K-A Inc., Amgen Manufacturing Limited, Amgen Research Munich GmbH, Amgen Rockville Inc., Amgen S.A., Amgen S.A.S., Amgen S.p.A., Amgen SF LLC, Amgen Singapore Manufacturing Pte. Ltd., Amgen Technology Ireland Unlimited Company, Amgen Technology Limited, Amgen USA Inc., Amgen Worldwide Holdings B.V., Avidia, Bergamo, BioVex, BioVex Inc., Catherex, Catherex, DeCODE Genetics, Dezima Pharma, Filgrastim and Pegfilgrastim, Five Prime Therapeutics, Five Prime Therapeutics Inc., Gensenta İlaç Sanayi ve Ticaret Anonim Şirketi, Ilypsa, Immunex, Immunex Corporation, Immunex Rhode Island Corporation, KAI Pharmaceuticals, KAI Pharmaceuticals Inc., Kinetix Pharmaceuticals, Laboratorio Quimico Farmaceutico Bergamo, MN Pharmaceuticals, Micromet, Nuevolution, Onyx Pharmaceuticals, Onyx Pharmaceuticals Inc., Onyx Therapeutics Inc., Otezla, Rodeo Therapeutics, Saga Investments Coöperatief U.A., Synergen, TeneoBio, TeneoBio Inc., Tularik, deCODE Genetics ehf, and llypsa Inc..
Read More
When was Amgen founded?

Amgen was founded in 1980.

How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The official website for the company is www.amgen.com. The medical research company can be reached via phone at (805) 447-1000, via email at investor.relations@amgen.com, or via fax at 805-447-1010.

This page (NASDAQ:AMGN) was last updated on 8/19/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.